ANI Pharmaceuticals CFO uses shares for tax withholding

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported tax-withholding share dispositions related to restricted stock vesting.

Accepted by SEC EDGAR 02/17/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported tax-withholding share dispositions related to restricted stock vesting. On February 12, 2026, 2,829 shares of common stock were withheld at $76.7 per share to cover taxes on 6,202 vested restricted shares. On February 14, 2026, 2,448 shares were withheld at $77.36 per share to cover taxes on 5,368 vested restricted shares. After these non-market transactions, Carey directly beneficially owned 170,083 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 5,277 shares

Exercise Price or Tax Liability 2 txns

Insider CAREY STEPHEN P.

Role SVP & CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,448	$77.36	$189K
Exercise Price or Tax Liability	Common Stock	2,829	$76.70	$217K

Holdings After Transaction: Common Stock — 170,083 shares (Direct)

Holdings Before and After: Common Stock, 175,360 to 170,083 shares (Direct)

Footnotes (2)

1. F1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,368 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANIP SVP & CFO Stephen P. Carey report on this Form 4?

Stephen P. Carey reported two tax-withholding share dispositions tied to restricted stock vesting. On February 12 and 14, 2026, ANI Pharmaceuticals common shares were withheld to satisfy tax obligations, leaving him with direct ownership of 170,083 shares afterward.

How many ANI Pharmaceuticals (ANIP) shares were used for tax withholding?

Two transactions used company shares to cover taxes. On February 12, 2026, 2,829 shares were withheld, and on February 14, 2026, another 2,448 shares were withheld in connection with vesting restricted stock awards.

What prices were used in the ANIP Form 4 tax-withholding transactions?

The tax-withholding dispositions used specific share values. On February 12, 2026, shares were valued at $76.7 each, and on February 14, 2026, shares were valued at $77.36 each, according to the reported Form 4 transactions.

How many ANIP shares does Stephen P. Carey own after these Form 4 transactions?

After the reported tax-withholding share dispositions, Stephen P. Carey directly beneficially owned 170,083 shares of ANI Pharmaceuticals common stock. This figure reflects his holdings following the February 12 and February 14, 2026, restricted stock vesting-related transactions.

What triggered the tax-withholding share dispositions reported by ANIP’s CFO?

The share dispositions were triggered by restricted stock vesting. Footnotes state shares were withheld for tax purposes under Rule 16(b)-3 when 6,202 and 5,368 restricted shares vested from grants originally reported in 2025 and 2024, respectively.

Are the ANIP Form 4 transactions open-market sales by the CFO?

No, the transactions are reported as tax-withholding dispositions, not open-market sales. Code F indicates shares were withheld to satisfy tax liabilities in connection with restricted stock vesting, rather than discretionary buying or selling in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		2,829	D	$76.7	172,531	D
Common Stock	02/14/2026		F(2)		2,448	D	$77.36	170,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,368 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.